0001354457-19-000467.txt : 20190923
0001354457-19-000467.hdr.sgml : 20190923
20190923093400
ACCESSION NUMBER: 0001354457-19-000467
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20190923
DATE AS OF CHANGE: 20190923
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: XYNOMIC PHARMACEUTICALS HOLDINGS, INC.
CENTRAL INDEX KEY: 0001697805
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38120
BUSINESS ADDRESS:
STREET 1: 609-610 21ST CENTURY TOWER
STREET 2: 40 LIANGMAQIAO ROAD, CHAOYANG DISTRICT
CITY: BEIJING
STATE: F4
ZIP: 100016
BUSINESS PHONE: 9493506999
MAIL ADDRESS:
STREET 1: 609-610 21ST CENTURY TOWER
STREET 2: 40 LIANGMAQIAO ROAD, CHAOYANG DISTRICT
CITY: BEIJING
STATE: F4
ZIP: 100016
FORMER COMPANY:
FORMER CONFORMED NAME: Bison Capital Acquisition Corp.
DATE OF NAME CHANGE: 20170621
FORMER COMPANY:
FORMER CONFORMED NAME: Bison Capital Acquisition Corp
DATE OF NAME CHANGE: 20170209
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: The Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
25-NSE
1
primary_doc.xml
X0203
0001354457
The Nasdaq Stock Market LLC
0001697805
XYNOMIC PHARMACEUTICALS HOLDINGS, INC.
001-38120
Suite 4202, K. Wah Centre
1010 Middle Huaihai Road
Shanghai
F4
CHINA
20031
9493506999
Common Stock
17 CFR 240.12d2-2(b)
Amy Horton
Hearings Advisor
2019-09-23
EX-99.25
2
xyndelistreason.txt
Delisting Determination,The Nasdaq Stock Market, LLC,
September 23, 2019, Xynomic Pharmaceuticals Holdings, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the common stock of Xynomic Pharmaceuticals Holdings, Inc.
(the Company), effective at the opening of the trading
session on October 3, 2019. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5101-2.
The Company was notified of the Staffs determination on
May 15, 2019. The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
July 15, 2019, denying the Company continued listing
and notified the Company that trading in the Companys
securities would be suspended on July 17, 2019.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on August 29, 2019.